OFIX Healthcare

Orthofix Medical Inc.

$8.76+0.11%

Price as of close on Nov 3, 2026 · Financials updated Oct 10, 2026

Basics

Sector: Healthcare
Industry: Medical Devices
Country: United States
Market cap: 354.1M USD
Enterprise value: 499.9M USD
Full-time employees: 1,605

Overall health

Drawback: less profitable than most peersless profitable than peers
Drawback: its shares are priced higher than most peers relative to what it earnspriced higher than peers for its earnings
About average: growth and risk (debt, liquidity and share-price swings)growth and risk

Ranks #815 of 1,157 healthcare companies (bottom 30%)

See how it ranks against its peers

Worth knowing

Shareholders being diluted. Shares outstanding up 102% from December 2022 to July 2026.
Orthofix Medical had 102% more shares at July 2026 than at December 2022, mostly from issuing stock (for pay, acquisitions or fundraising). Each existing share now owns a smaller slice of the business.Orthofix Medical had 102% more shares at July 2026 than at December 2022, mostly from issuing stock. Each existing share now owns a smaller slice of the business.
Valuation signals disagree. Cheaper than 50% of peers on free cash flow, but only 0% on earnings.
Relative to its free cash flow, Orthofix Medical looks cheaper than 50% of peers; relative to its earnings, cheaper than only 0%. The valuation score blends the two, so look at which measure fits this business best.
Not profitable yet. Reported a loss in the 12 months to June 2026.
Orthofix Medical reported a net loss over the last twelve months, so earnings-based measures can't show it as cheap.

StockQuotient Score

41/ 100

Oct 5 41 → Nov 4 41

Valuation

Is the price right?

39/100

Weak

3/3 inputs reported · High confidence

Since last quarter: No major changeValuation also moves with the share price every day.

Why

Weaker than most peers on:

▼ Earnings yield

Compare with peers

Behind the score

Sector-normalized EBITDA, earnings, and free cash flow yields.

Earnings yield-17.3%

SEC filings · 12 months to Jun 2026Negative (a loss or cash outflow), so it counts as zero whatever the share price30% base weight · Z-score -1.00Sector median: 0.0148 · MAD: 0.0148

EBITDA yield2.9%

SEC filings · 12 months to Jun 2026Reported value50% base weight · Z-score -0.29Sector median: 0.0401 · MAD: 0.0401

Free cash flow yield-7.8%

SEC filings · 12 months to Jun 2026 · operating cash flow − capital spendingNegative (a loss or cash outflow), so it counts as zero whatever the share price20% base weight · Z-score 0.00Sector median: 0.0000 · MAD: 0.0000

Other data (not scored)

Book yield120.3%

SEC filings · latest balance sheetReported valueInformational · 0% composite weightSector median: 0.3716 · MAD: 0.2313

Growth

Is it growing?

52/100

Moderate

3/3 inputs reported · High confidence

Since last quarter: No major change

Why

Mixed versus peers:

▲ 3-yr revenue
▼ Revenue growth

Compare with peers

Behind the score

Revenue and earnings-per-share growth over one year, and revenue growth over three years.

Earnings per share growthUnavailable

Still loss-making, but the loss per share narrowed33% base weight · Z-score 0.29Sector median: 0.0976 · MAD: 0.2991

3-year revenue growth11.7%

SEC filings · 3 years to Jun 2026Reported value33% base weight · Z-score 0.69Sector median: 0.0584 · MAD: 0.0840

Revenue growth3.0%

SEC filings · 12 months to Jun 2026Reported value33% base weight · Z-score -0.32Sector median: 0.0609 · MAD: 0.0974

Profitability

Does it earn well?

30/100

Weak

3/3 inputs reported · High confidence

Since last quarter: No major change

Why

Weaker than most peers on:

▼ ROA
▼ ROIC
▼ Operating margin

Compare with peers

Behind the score

Return on invested capital, operating margin, and return on assets.

Operating margin-4.7%

SEC filings · 12 months to Jun 2026Reported value33% base weight · Z-score -0.97Sector median: 0.0706 · MAD: 0.1217

Return on assets-7.1%

SEC filings · 12 months to Jun 2026Reported value33% base weight · Z-score -1.63Sector median: 0.0166 · MAD: 0.0537

Return on invested capital-5.7%

SEC filings · 12 months to Jun 2026Reported value33% base weight · Z-score -1.03Sector median: 0.0471 · MAD: 0.1004

Other data (not scored)

Gross margin71.3%

SEC filings · 12 months to Jun 2026Reported valueInformational · 0% composite weightSector median: 0.4697 · MAD: 0.2310

Return on equity-14.4%

SEC filings · 12 months to Jun 2026Reported valueInformational · 0% composite weightSector median: 0.0330 · MAD: 0.1225

Risk

Debt, liquidity, price swings

Moderate

Moderate relative risk

3/3 inputs reported · High confidence

Since last quarter: No major change

Why

Held back by:

▼ Debt / equity

Compare with peers

Behind the score

Relative to sector peers: 0 = lower relative risk · 1 = moderate · 2 = higher. Based on leverage, beta and liquidity.

Beta0.62

Yahoo Finance · 5-year monthly beta vs the marketReported value33% base weight · Z-score 0.02Sector median: 0.6250 · MAD: 0.3380

Current ratio2.84×

SEC filings · latest balance sheetReported value33% base weight · Z-score 0.18Sector median: 2.5860 · MAD: 1.3850

Debt / equity0.52×

SEC filings · latest balance sheetReported value33% base weight · Z-score -1.45Sector median: 0.2215 · MAD: 0.2039

Valuation, growth and profitability scores: higher is better. Risk: 0 is lower, 2 is higher. Risk is a relative proxy, not a bankruptcy probability. Scores depend on available sector peers.

Questions investors ask about Orthofix Medical

Is Orthofix Medical getting weaker?: Its latest SEC filing (Aug 5, 2026) showed no major changes. Its overall score is unchanged at 41/100 since Oct 28, 2026.
How is Orthofix Medical valued vs its peers?: Priced higher than most peers relative to what it earns. Valuation scores 39/100 against 1,393 healthcare peers. Earnings yield -17.3% vs a peer median of 1.5% (weaker than 100% of peers).Earnings yield -17.3% vs peers 1.5% (weaker than 100% of peers).
Is Orthofix Medical growing?: At about the same pace as its peers. Growth scores 52/100 against 1,393 healthcare peers. 3-year revenue growth 11.7% vs a peer median of 5.8% (stronger than 67% of peers).3-year revenue growth 11.7% vs peers 5.8% (stronger than 67% of peers). Revenue growth 3.0% vs a peer median of 6.1% (weaker than 61% of peers).Revenue growth 3.0% vs peers 6.1% (weaker than 61% of peers).
How profitable is Orthofix Medical?: Less profitable than most of its peers. Profitability scores 30/100 against 1,393 healthcare peers. Return on assets -7.1% vs a peer median of 1.7% (weaker than 73% of peers).Return on assets -7.1% vs peers 1.7% (weaker than 73% of peers).
How risky is Orthofix Medical?: Moderate risk relative to 1,393 healthcare peers, judged on debt, liquidity and share-price swings. Debt / equity 0.52× vs a peer median of 0.22× (weaker than 67% of peers).Debt / equity 0.52× vs peers 0.22× (weaker than 67% of peers). A relative measure, not a bankruptcy probability.

Latest filing: what changed

Quarter ended Jun 30, 2026 · filed Aug 5, 2026 · compared with the quarter ended Mar 31, 2026

No major changes

	Previous quarter	Latest quarter	Change
Revenue (12 months)	825.4M USD	833.2M USD	+0.9%
Net income (12 months)	−60.0M USD	−61.7M USD	+2.9%
Operating margin	-5.7%	-4.7%	+1.0 pts
Free cash flow (12 months)	−4.4M USD	−27.8M USD	+529.1%
Debt	221.3M USD	221.6M USD	+0.1%
Cash	120.3M USD	103.8M USD	−13.7%
Shares outstanding	40.4M	40.7M	+0.8%

From the company’s own SEC filings, as filed. Twelve-month figures roll forward one quarter at a time.

Industry valuation context

Industry: Medical Devices · 33 companies

Valuations in Medical Devices are near the bottom of their range since 2016.

7% of months since 2016 were valued lower than now.
4% of companies are in the most expensive fifth of their own price-to-sales history.
Over 24 months, company values −8% and earnings +33% (medians): earnings grew faster than prices.
Median price-to-sales is +20% vs the whole market, against a usual +109%.

2016Shaded: most expensive fifth of its range2026

Financials

Fiscal years from SEC annual filings · change vs the prior year

Key ratios	FY 2021	FY 2022	FY 2023	FY 2024	FY 2025	Change
Gross margin	75.3%	73.2%	65.1%	68.3%	68.8%	▲ 0.6 pts
Operating margin	-1.8%	-2.9%	-18.6%	-10.6%	-9.9%	▲ 0.7 pts
Net margin	-8.3%	-4.3%	-20.3%	-15.8%	-11.2%	▲ 4.5 pts
Return on assets (ROA)	-8.1%	-4.3%	-16.4%	-14.1%	-10.8%	▲ 3.3 pts
Return on equity (ROE)	-11.4%	-5.9%	-25.3%	-25.0%	-20.5%	▲ 4.6 pts
Free cash flow margin	0.1%	-7.1%	-14.2%	-1.1%	-0.2%	▲ 1.0 pts
Current ratio	2.55×	3.06×	2.54×	2.57×	2.45×	▼ 4.8%
Quick ratio	1.76×	1.86×	1.20×	1.45×	1.43×	▼ 0.8%
Debt to equity	—	—	0.16×	0.31×	0.35×	▲ 12%

OFIX price history

Price history is added with the daily price update and will appear after the next one.

Similar companies

Sector leaderboards

BB Biotech AGBBZA.DE100/ 100

Arbutus Biopharma CorporationABUS97/ 100

Q32 Bio Inc.QTTB97/ 100

Bringing the fundamentals into focus…

Overall health

Drawback: less profitable than most peersless profitable than peers

Drawback: its shares are priced higher than most peers relative to what it earnspriced higher than peers for its earnings

About average: growth and risk (debt, liquidity and share-price swings)growth and risk

Ranks #815 of 1,157 healthcare companies (bottom 30%)

See how it ranks against its peers

Worth knowing

Shareholders being diluted. Shares outstanding up 102% from December 2022 to July 2026.

Orthofix Medical had 102% more shares at July 2026 than at December 2022, mostly from issuing stock (for pay, acquisitions or fundraising). Each existing share now owns a smaller slice of the business.Orthofix Medical had 102% more shares at July 2026 than at December 2022, mostly from issuing stock. Each existing share now owns a smaller slice of the business.

Valuation signals disagree. Cheaper than 50% of peers on free cash flow, but only 0% on earnings.

Relative to its free cash flow, Orthofix Medical looks cheaper than 50% of peers; relative to its earnings, cheaper than only 0%. The valuation score blends the two, so look at which measure fits this business best.

Not profitable yet. Reported a loss in the 12 months to June 2026.

Orthofix Medical reported a net loss over the last twelve months, so earnings-based measures can't show it as cheap.

Questions investors ask about Orthofix Medical

Is Orthofix Medical getting weaker?

Its latest SEC filing (Aug 5, 2026) showed no major changes. Its overall score is unchanged at 41/100 since Oct 28, 2026.

How is Orthofix Medical valued vs its peers?

Priced higher than most peers relative to what it earns. Valuation scores 39/100 against 1,393 healthcare peers. Earnings yield -17.3% vs a peer median of 1.5% (weaker than 100% of peers).Earnings yield -17.3% vs peers 1.5% (weaker than 100% of peers).

Is Orthofix Medical growing?

At about the same pace as its peers. Growth scores 52/100 against 1,393 healthcare peers. 3-year revenue growth 11.7% vs a peer median of 5.8% (stronger than 67% of peers).3-year revenue growth 11.7% vs peers 5.8% (stronger than 67% of peers). Revenue growth 3.0% vs a peer median of 6.1% (weaker than 61% of peers).Revenue growth 3.0% vs peers 6.1% (weaker than 61% of peers).

How profitable is Orthofix Medical?

Less profitable than most of its peers. Profitability scores 30/100 against 1,393 healthcare peers. Return on assets -7.1% vs a peer median of 1.7% (weaker than 73% of peers).Return on assets -7.1% vs peers 1.7% (weaker than 73% of peers).

How risky is Orthofix Medical?

Moderate risk relative to 1,393 healthcare peers, judged on debt, liquidity and share-price swings. Debt / equity 0.52× vs a peer median of 0.22× (weaker than 67% of peers).Debt / equity 0.52× vs peers 0.22× (weaker than 67% of peers). A relative measure, not a bankruptcy probability.

Previous quarter

Latest quarter

Change

Revenue (12 months)

825.4M USD

833.2M USD

+0.9%

Net income (12 months)

−60.0M USD

−61.7M USD

+2.9%

Operating margin

-5.7%

-4.7%

+1.0 pts

Free cash flow (12 months)

−4.4M USD

−27.8M USD

+529.1%

Debt

221.3M USD

221.6M USD

+0.1%

Cash

120.3M USD

103.8M USD

−13.7%

Shares outstanding

40.4M

40.7M

+0.8%

Key ratios

FY 2021

FY 2022

FY 2023

FY 2024

FY 2025

Change

Gross margin

75.3%

73.2%

65.1%

68.3%

68.8%

▲ 0.6 pts

Operating margin

-1.8%

-2.9%

-18.6%

-10.6%

-9.9%

▲ 0.7 pts

Net margin

-8.3%

-4.3%

-20.3%

-15.8%

-11.2%

▲ 4.5 pts

Return on assets (ROA)

-8.1%

-4.3%

-16.4%

-14.1%

-10.8%

▲ 3.3 pts

Return on equity (ROE)

-11.4%

-5.9%

-25.3%

-25.0%

-20.5%

▲ 4.6 pts

Free cash flow margin

0.1%

-7.1%

-14.2%

-1.1%

-0.2%

▲ 1.0 pts

Current ratio

2.55×

3.06×

2.54×

2.57×

2.45×

▼ 4.8%

Quick ratio

1.76×

1.86×

1.20×

1.45×

1.43×

▼ 0.8%

Debt to equity

—

0.16×

0.31×

0.35×

▲ 12%